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 6
All patients and their parents that accepted to join the study, with the result that 
knowledge about this topic has been greatly increased. 
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Summary 
Objective: Preterm infants usually have low retinol status. We have therefore 
evaluated a new protocol designed to improve vitamin A status in very low birth 
weight infants (VLBW, birth weight < 1,500 g). Since the new protocol also changed 
the supplementation of vitamins D, E and K, their plasma concentrations were also 
analyzed to characterize the infants’ status of all fat-soluble vitamins. 
Design: An open intervention trial was conducted where vitamin A was given in a 
human milk fortifier. The daily intake of vitamin A was increased by 8% compared to 
the previous regimen (reference), and given mixed with human milk instead of as a 
bolus. In this modified regimen, the intake of the other fat-soluble vitamins also 
changed due to different vitamin content in the supplementation used. Vitamin D 
intake was reduced by 10%; vitamin E intake was reduced by 6% in the modified 
protocol and vitamin K intake was increased by 132% compared to the reference 
regimen. Blood samples were collected at inclusion and at discharge from hospital. 
The plasma concentrations of the different vitamins were analyzed with high 
performance liquid chromatography. The daily intake of all the fat-soluble vitamins 
and their plasma concentrations were compared to the vitamin protocol normally used 
in Norwegian hospitals. 
Results: Sixty VLBW infants were included and 53 completed the study. At 
discharge from hospital, the reference group had lower plasma retinol concentrations 
compared to the modified group (0.30 vs. 0.45 µM, P=0.005). Fewer infants in the 
modified group had plasma retinol levels below 0.35 µM (indicating reduced hepatic 
stores) compared to the infants in the reference group (44% vs. 69%, P = 0.04). At 
discharge the reference group had higher plasma 25(OH)vitamin D than the modified 
group (171 vs. 110 μM, P=0.003). The plasma concentrations of α-tocopherol were 
not significantly different between the two groups (31 vs. 39 μM) at discharge from 
hospital. The plasma phylloquinone concentration was non-significantly lower in the 
reference group compared to the modified group (1.0 vs. 2.1 ng/ml). 
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Conclusions: The modified regimen improved vitamin A status among VLBW 
infants at discharge compared to the reference protocol. More studies are needed to 
establish the optimal plasma retinal concentration for preterm infants and how this 
can be achieved. Whether this will translate into lower vitamin A-related morbidity 
and/or mortality in these children warrants further investigation. Vitamin D status 
was also improved in the modified group by giving a plasma concentration in the 
normal range compared to the high mean level in the reference group. Vitamin E 
status was similar in the two groups and vitamin K status was not significantly 
improved. 
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Abbrevations 
AGA adequate for gestational age 
AAP American Academy of Pediatrics 
BPD bronchopulmonary dysplasia 
CLD chronic lung disease 
ELBW extremely low birth weight  
EN enteral nutrition 
ESPGHAN 
European Society of Paediatric Gastroenterology, Hepatology and 
Nutrition 
GA gestational age 
IUGR intrauterine growth retardation 
IVH intraventricular haemorrhage 
LBW low birth weight 
NCPAP nasal continuous positive airway pressure 
NEC necrotizing enterocolitis 
NICU neonatal intensive care unit 
PN parenteral nutrition 
RDS respiratory distress syndrome 
ROP retinopathy of prematurity 
SGA small for gestational age 
VLBW very low birth weight 
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1. Introduction 
1.1 Definition of preterm infants 
 
 
ue 
t of 
 
functional gastrointestinal tract and poor tolerance of parenteral 
nutrition (3;4).  
 
1.2 Prevalence of preterm birth 
s risen because of more knowledge about treatment 
during pregnancy and after birth. 
Infants born prior to 36 weeks of completed gestation are called preterm infants (2). 
These infants can be categorized in groups based on birth weight. Low birth weight 
infants (LBW) have a birth weight less than 2500 g. Infants with birth weight below 
1500 g are termed very low birth weight (VLBW), whereas those with birth weight 
less than 1000 g are termed extremely low birth weight (ELBW). Infants born smaller
than expected for their gestational age (GA) are often denoted “small for gestational 
age” (SGA) and “intrauterine growth retarded” (IUGR). SGA infants are below the 
10th or 3rd percentile for weight at birth, depending on source of definition (2). This is
probably a heterogeneous group containing both the infants who are born small d
to genetic disposition and the infants who are IUGR because of lack of nutrient 
supply according to their needs. The prevalence of IUGR is much higher among 
preterm infants than among term infants. Early nutritional intervention is important 
for later outcomes in these infants, as nutrition plays a key role in the developmen
multiple organ systems. The problem in managing this nutrient intervention is an
immature or dys
Approximately 850 very low birth weight infants (<1500 g) are born in Norway 
every year. This accounts for approximately 1.5 % of the total number of births 
which amounts to nearly 60 000. In the last 30 years survival of premature children 
with birth weight below 1500 g ha
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1.3 Survival and clinical conditions 
The incidence and severity of all complications of prematurity are roughly inversely 
related to gestation and birth weight. Adequate nutrition during the first days after 
birth is probably of vital importance for optimal growth and further development. 
Early nutritional deficits are linked to impairments of intellectual performance, 
reduced work capacity and elevated risk of coronary heart disease and metabolic 
syndrome later in life (5). 
Although apnoea is associated with immaturity of the respiratory control system, it 
may also be the presenting sign of other diseases or pathophysiological conditions 
that affect preterm infants. Apnoea is defined as the cessation of pulmonary airflow 
for a specific time interval, usually longer than 10 to 20 seconds. Bradycardia often 
accompanies prolonged apnoea. Apnoea is divided into two groups, central and 
obstructive apnoea. Central apnoea refers to a complete cessation of airflow and 
respiratory efforts with no chest wall movements, causing a lack of activity in the 
respiratory control centre. In obstructive apnoea, no airflow is exhibited, but the chest 
wall movements continue. A combination of these two events, mixed apnoeas, is the 
most frequent type seen in preterm infants. The incidence of apnoea increases as 
gestational age decreases (6;7). 
Immaturity of the respiratory system with surfactant deficiency results in respiratory 
distress syndrome (RDS). This disorder is also called hyaline membrane disease or 
surfactant deficiency syndrome and is treated with oxygen, N-CPAP (nasal 
continuous positive airway pressure), surfactant administration and mechanical 
ventilation (8). 
Chronic lung disease (CLD) was earlier named bronchopulmonary dysplasia (BPD). 
This is usually defined as the need for supplemental oxygen at 36 weeks 
postmenstrual age. It results from a combination of lung immaturity, oxygen toxicity, 
inflammatory and free radical mediated lung injury. Babies with CLD may require 
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supplemental oxygen for months and are at increased risk of respiratory infections 
(7;8). 
Periventricular or intraventricular haemorrhage (IVH) is due to bleeding from the 
immature rich capillary bed of the germinal matrix lining (7) the central ventricles. 
Risk factors include asphyxia and changes in cerebral blood flow due to hypertension 
or rapid intravenous fluid infusion. It is graded by severity from grade I to grade IV. 
While lower grades of IVH have a good prognosis, grades III and IV are often 
associated with hydrocephalus and neurological abnormalities, such as cerebral palsy, 
and higher mortality (7;8). 
Severe neurodevelopmental impairments like cerebral palsy, mental retardation, 
blindness and deafness occur in 10-15 % of VLBW infants. More subtle delays in 
language, attention deficits and social and behavioural difficulties are common. 
Eating disorders and growth impairments are also more often seen in this group (7;8). 
Retinopathy of prematurity (ROP) results from a disruption of the normal process of 
vascularisation of the retina, which in effect leads to new vessel formation and 
fibrous scarring. Although ROP can result from excessive oxygen exposure most 
cases occur in ELBW infants with multiple other problems. Severity is classified on 
the basis of location and extent of ROP from grade 1 to grade 4. Most mild ROP 
regresses spontaneously, but eye examinations are required to detect progressive 
ROP, which requires therapy to reduce the chances of blindness (9). 
Hypoglycaemia is common in the preterm infant due to decreased glycogen stores 
and increased glucose requirements. Hyperglycaemia can also occur in VLBW 
infants, due to high glucose infusion rates, reduced insulin secretion and impaired 
insulin sensitivity (8). 
From 25 weeks GA the gastrointestinal tract is structurally ready and can absorb 
nutrients, but due to immature gut motility and delayed gastric emptying feeding 
problems are frequent. Thus, feed intolerance and gastro-oesophageal reflux are 
common (10). There is evidence that rapid advancement of enteral feeds is associated 
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with increased risk of necrotising enterocolitis (NEC) (11;12). This is due to an 
inflammatory process in the bowel wall that may lead to bowel necrosis. Alterations 
in gut blood flow, hypotension, hypoxia, infection and the way of feeding have all 
been implicated, but their exact contribution remains unclear (8). A systematic review 
concluded that early introduction of enteral feeding shortens the time to full feeds as 
well as the length of hospitalisation without an increase in the rate of NEC (13). 
Breast milk has been demonstrated to have a protective effect against NEC (14).  
 
1.4 Nutrition 
1.4.1 Growth 
At birth the preterm infant is in a phase of extreme growth. Normally there is a period 
of about a week before the infant has reached its initial birth weight. Among ELBW 
infants, this initial weight loss can be approximately 15-20 % of the birth weight (15). 
Weight gain is only possible after this first period (16) and when the energy intake 
exceeds energy expenditure. The initial weight loss seen in preterm infants is by some 
experts thought to be a catabolic state, caused by low nutrient supply in addition to 
changes in fluid balance (15;17). Ziegler et al and others believe that the growth 
retardation often seen in preterm infants is due to malnutrition (17). 
Postnatal growth restriction is common among preterm infants and more infants may 
be defined as SGA at the time of discharge from hospital than at time of birth (18). 
This indicates that the nutrient requirements have not been adequately met during 
hospital stay. 
Studies indicate that the growth restriction starts at hospital, lasts through all 
childhood and may persist until age 4 to 7 years before these infants regain their lost 
prenatal growth (19). A Norwegian study showed that preterm infants with birth 
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weight less than 2 kg, by the time they were 5 and 11 years had lower weight and 
were shorter compared to children with normal birth weight (20).   
Determining nutritional requirements in preterm infants requires an agreed-upon 
reference standard. The most commonly applied and accepted standard is that of 
intrauterine growth (16). However, this standard is rarely achieved in clinical 
practice, either in terms of growth rate or body composition (21). Nevertheless, 
intrauterine growth remains an ideal goal. 
1.4.2 Nutritional requirements 
At birth preterm infants have limited stores of many nutrients as accumulation from 
the mother to the fetus (accretion) occurs predominantly in the last trimester (2;7). 
They are poorly equipped to withstand inadequate nutrition as the endogenous 
reserves of an infant with a birth weight of 1000 g are theoretically only sufficient for 
four days if unfed (22). From continuous intravenous nutrient supply via the 
umbilical cord, the infant must adjust to exogenous supply of nutrients from the 
gastrointestinal tract and endogenous production of energy yielding nutrients in 
between meals (7).  
Because of the small volume of the stomach and low tolerance of enteral feeds, it is 
generally accepted that the VLBW infant needs parenteral nutritional 
supplementation while enteral feeds are gradually increased (2). 
Immature metabolic responses and limited stores of nutrients, in addition to other 
complications, make nutrition to this group important and complicated (23). 
1.4.3 Macronutrients 
In an article, Ziegler described the body composition of a reference fetus using 
literature reports of whole body chemical analysis of fetuses born prematurely (24). 
This report is still the accepted representation of human fetal nutrient accretion. The 
rate of fetal nutrient accretion and weight gain change throughout gestation. Fetal 
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energy accretion is 24 kcal/kg/day between 24 and 28 weeks, and increases to 28 
kcal/kg/day through the rest of the gestation. An energy balance of 25-30 kcal/kg/day 
represents an achievable goal for premature infants. This accumulation is specific to a 
rate of protein and fat accretion. Protein accretion is 2 g/kg/day in the beginning of 
the third trimester and declines slightly. Fat accretion increases throughout the third 
trimester. Early gestation is therefore characterized by accumulation of lean tissue, 
while more fat and less lean tissue is accreted in late gestation. Because fat tissue is 
energy dense compared to lean tissue, the rate of weight gain is reduced from 18 
g/kg/day at 24-28 weeks to 16 g/kg/day at 32-36 weeks.  
To achieve this optimal accretion of nutrients and weight gain, it is essential to ensure 
adequate intake of macronutrients. The energy need of the preterm infant is 
approximately 105-130 kcal/kg/day and the protein need is approximately 3.5-4.0 
g/kg/day (16). The daily protein accretion at around 2 g/kg/day in the third trimester 
is probably achieved if the protein intakes are accompanied by at least 110 
kcal/kg/day enterally or 80 non-protein kcal/kg parenterally (21). Early 
administration of protein are associated with higher weight gain (25).  
As fat is energy dense, it is the preferred source of energy, but there is a risk of 
malabsorption among VLBW infants, due to low pancreatic lipase, low bile salt pools 
and possible reduced activity of lingual lipase. Human milk that is not pasteurised is 
better tolerated than heat-treated human milk because it contains some bile salt 
stimulated lipase (26). Medium chain triglycerides are often used as an energy source 
for the preterm infant because of theoretically improved fat absorption. An advantage 
with respect to fat or nitrogen balance, when using this energy source has not, 
however, been demonstrated (27;28). The risk of developing essential fatty acid 
deficiency is great in the VLBW and ELBW infants. It is thus necessary to provide 
enough linoleic and linolenic acid to cover the need for essential fatty acids (29). 
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1.4.4 Parenteral nutrition 
Most of the VLBW and ELBW preterm infants will receive parenteral nutrition for at 
least the first days after birth. The administration of parenteral nutrients is usually 
administered together with minimal enteral feeding of human milk (30). Given 
parenterally, approximately 120 kcal/kg/day and 3.5 g protein/kg/day are needed to 
ensure intrauterine growth and positive nitrogen balance (31). Early parenteral 
administration of protein as amino acids is associated with better growth parameters 
at 36 weeks of gestation and fewer infants with suboptimal head circumference at 18 
months (25). Hyperglycaemia, hyperlipidemia and metabolic acidosis are metabolic 
complications seen in sick preterm infants when administering parenteral nutrition 
(32), and this is probably the reason why many are reluctant to increase parenteral 
infusions to reach optimal levels of nutrient accretion.  
1.4.5 Enteral nutrition 
Minimal enteral feeding is started as early as possible after birth. If available, the 
mothers own milk is used; alternatively donor milk (human milk collected from other 
lactating women) is used. Neither of these milk-alternatives is pasteurised in NICUs 
in Norway. The advantages of early and minimal enteral feeding have been shown 
(2). The use of human milk has advantages such as improved feed tolerance (33), 
reduced risk of NEC (14), reduced risk of sepsis (14;34) and long-term 
neurodevelopmental advantages (35-37). Specific bioactive factors, such as Ig A, 
lactoferrin, lysozyme, oligosaccharides, nucleotides, growth factors, enzymes and 
cellular components are all represented in human milk and will have a positive effect 
in the gut of the preterm infant. Some of the factors can enhance the development of 
the gut flora and some help in the maturation of the gut (7). 
Normally human milk is supplemented with protein, minerals and vitamins when the 
preterm infant has achieved an intake of a certain volume of milk per kg. The 
different NICUs in Norway differ in which volume of milk is considered to be the 
appropriate milk volume for starting supplementation. The time and volume 
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appropriate to start supplementation also depends on the toleration of the enriched 
and hyper osmotic nutrition. Many of the VLBW infants receive enteral feed of 
approximately 18% of their weight, and this volume of 180 ml/kg is often considered 
full milk volume. Some NICUs do not enrich the human milk with proteins etc. 
before full milk volume is achieved, but in our department a supplementation is often 
started if considered possible at 150 ml/kg.  Increasing the volume instead of 
supplementing the milk is a possibility to give the preterm infant more energy and 
nutrients. This may be possible in the LBW infant, but the VLBW and ELBW infants 
need supplemented milk. On the marked, there are different commercially produced 
human milk fortifiers, which mainly supply extra protein and minerals to the milk. 
The energy content of the milk will also be higher with this supplementation. 
 
1.5 Fat-soluble vitamins 
Vitamin A, D, E and K are fat-soluble vitamins. The premature infant need, as do all 
fetuses and term infants eventually, to receive supplementation of these vitamins in 
order to achieve normal development. Metabolites of the fat-soluble vitamins fulfil a 
multitude of functions essential for life.   
In the last trimester of the pregnancy, an accumulation in the fetus of fat-soluble 
vitamins occurs. This explains the fact shown in the literature that premature infants 
at birth have lower plasma levels and lower reserves of fat-soluble vitamins than full-
born infants. Plasma levels of vitamin K are low both in term-born and VLBW 
infants. There is little knowledge about the status of fat-soluble vitamins in the 
prematurely born infant fed human milk, but one recent study showed great 
differences in plasma levels between VLBW and term-born infants (1). Human milk 
contains only small amounts of fat-soluble vitamins. It is therefore standard 
procedure to supply these vitamins to the preterm infant.  
 19
1.5.1 Vitamin A 
Vitamin A is an important micronutrient affecting infant health. Retinol, 
retinaldehyde and retinoic acid are compounds referred by the term vitamin A. 
Retinol may be obtained directly from foods of animal origin, be formed in the body 
from metabolism of β-carotene or supplied from a supplement as retinyl esters. 
Absorption of retinyl esters involves hydrolysis and complexation with bile acids in 
the gut lumen before uptake by enterocytes (21). The availability of a specific carrier 
protein, cellular retinol binding protein type 2 (RBP), may be limited in the preterm 
infant and it is essential for the metabolism of vitamin A within these cells and 
transfer into the lymphatic system (38). After absorption, retinol is bound to RBP in 
the liver and transported in plasma as the retinol-RBP complex. Circulating retinol is 
delivered to target tissues via a specific membrane receptor and is oxidised within the 
cell to its active metabolite, retinoic acid (39). The precise mechanisms by which 
retinoic acid affects intracellular activity are complex and incompletely defined 
(40;41).  
Metabolites of vitamin A are involved in the regulation of growth and differentiation 
of various types of cells, including skin and epithelial cells of the respiratory tract 
(42). Moreover, vitamin A is required for the formation of the photosensitive visual 
pigment in the retina, and for normal reproductive and immune functions (42). 
Consequently, deficiency of vitamin A may predispose preterm infants to chronic 
lung disease and xerophtalmia and increase the risk for infections (43). 
In developed countries, most infants are provided with sufficient vitamin A supplies. 
Term infants receive adequate levels of vitamin A in utero, and human milk contains 
sufficient amounts of vitamin A to maintain normal growth and development during 
their first 6 months (44). In contrast, preterm infants have low plasma concentrations 
of retinol and retinol binding protein at birth, reflecting low hepatic stores (44). Thus, 
preterm infants need supplementation (45), but controversy exists regarding the 
optimal dose and way of administration.  
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The plasma concentration of retinol is a commonly used biochemical marker of 
vitamin A status. Plasma retinol concentrations less than 0.70 µM indicate 
biochemical vitamin A deficiency (44), whereas levels below 0.35 µM reflect 
reduced hepatic stores and clinical signs of deficiency in infants older than six 
months (46). Low plasma retinol concentration is associated with an increased risk 
for developing chronic lung disease, with an odds ratio of 2.04 for each 0.25 µM 
reduction in plasma retinol (47).The plasma reference level according to the 
laboratory that analyzed the blood samples in this study, Vitas AS, is above 0.7 µM 
for both children and adults.  
The purpose of nutrition therapy in preterm infants is to approximate intrauterine 
accretion ratio (16). Human milk is the preferred nutritional source in enteral feeding 
in preterm infants (16), but the content of vitamin A in human milk is too low to meet 
the high requirement among these infants. The vitamin A concentration of human 
milk varies according to several factors, but preterm milk has higher vitamin A 
content compared to term milk after the first week of lactation. At approximately 35 
days postpartum age, the vitamin A content of preterm milk ranges from 83 to 100 µg 
per 100 ml according to Tsang et al (21). This differs somewhat from the vitamin A 
concentration in human milk samples from this current study, 54 μg per 100 ml. 
Vitamin A is usually given as a parenteral or enteral supplement, but the dosages for 
both parenteral and enteral vitamin A supplements vary markedly between paediatric 
institutions (2;16). The recommendations for vitamin A intake for preterm infants 
range from 30 to 1000 µg/day (16;21;48). It was reported that VLBW infants, given 
the reference Norwegian supplementation of vitamin A (750 μg/day), had a plasma 
retinol concentrations at discharge from hospital of 0.30 µM, indicating vitamin A 
deficiency (1). In contrast, the plasma concentration of retinol among term infants 
was 0.72 µM (1). Possible explanations for the observed low plasma retinol 
concentrations among the VLBW infants include the dose of vitamin A supplement, 
impaired intestinal absorption or subsequent transport and/or metabolism of vitamin 
A.   
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The results of a randomized trial and a systematic Cochrane review show that 
intramuscular vitamin A injection may reduce chronic lung disease and death in 
VLBW infants (49;50). This may suggest that an insufficient absorption of vitamin A 
is a likely explanation for the low plasma retinol levels found in VLBW infants. 
However, this route of administration is not implemented in most institutions, 
probably because the reduced morbidity and mortality obtained with repeated 
intramuscular injections must be weighed against the acceptability and tolerance of 
such treatment in VLBW infants (51). Hence there is a need to improve enteral 
vitamin A supplementation. 
1.5.2 Vitamin D 
There are different vitamin D metabolites (52).  Exposure of the skin to ultraviolet 
light catalyses the synthesis of vitamin D3 (cholecalciferol) from 7-
dehydrocholesterol. The other major form of vitamin, D2 (ergocalsiferol), is the 
product of the ultraviolet light-induced conversion of ergosterol in plants. Dietary 
vitamin D is readily absorbed from the small intestine and transported in 
chylomicrons to the liver where conversion to 25-hydroxy vitamin D (25(OH)vitamin 
D) takes place.  25(OH)vitamin D is further hydroxylated in the kidney to yield 1,25-
dihydroxy vitamin D (1,25(OH)2vitamin D) and 24,25-dihydroxy vitamin D 
(24,25(OH)2vitamin D). 1,25(OH)2vitamin D is the hormonal circulating and 
biologically active metabolite of vitamin D. In addition to ensuring adequate 
absorption of calcium, 1,25(OH)2vitamin D contributes to plasma calcium regulation 
by increasing bone resorption synergistically with parathyroid hormone and 
stimulating the reabsorption of calcium by the kidney. Vitamin D is thus essential for 
the proper formation of the skeleton and for mineral homeostasis. Hypocalcemia and 
increased parathyroid hormone secretion induce synthesis of 1,25(OH)2vitamin D 
after birth in both term-born and preterm neonates. Nevertheless, serum 
concentrations of 25(OH)vitamin D are a rate-limiting factor in the synthesis of 
1,25(OH)2vitamin D (53). A recent publication demonstrats a possible protective 
effect of vitamin D against development of multiple sclerosis (54). The vitamin D 
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requirement of humans can be met if their skin is exposed to a sufficient amount of 
sunlight or artificial ultraviolet light radiation. Obviously, such light exposure is not 
possible in the VLBW infants, and vitamin D must be supplemented. 
Measurement of plasma concentration of 25(OH)vitamin D is the commonly used 
biochemical marker of vitamin D status. Among infants, plasma 25(OH)vitamin D 
concentration ranges from approximately 62 to 75 nM  (55), whereas the reference 
range for children according to the analysing laboratory, Vitas AS, is between 25 to 
130 nM and for adults the reference ranges from 50 to 150 nM. 
Both in term and preterm newborn, 25(OH)vitamin D concentrations in cord blood 
are lower than 25(OH)vitamin D concentrations found in maternal blood. Newborn 
blood concentrations are correlated with blood concentrations in the mother (56). 
Maternal vitamin D deficiency will reduce the transplacental transfer to the fetus of 
25(OH)vitamin D, resulting in lower stores in the infants at birth (57). Preterm infants 
are born with plasma concentrations of 25(OH)vitamin D that are 20-30% lower than 
their mother’s plasma 25(OH)vitamin D (57). The vitamin D requirements of preterm 
infants are influenced by the body stores at birth, which in turn are related to the 
length of gestation and maternal stores. It is shown that in infants born after 28 wk of 
gestation, activation of vitamin D is operative as early as 24 h after birth. Thus, 
vitamin D supplementation just after birth improves vitamin D nutritional status as 
evidenced by rising plasma 25(OH)vitamin D concentrations (53). 
Controversies exist regarding the ideal supplementation of vitamin D to the preterm 
infant. The European Society of Paediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN) (48) recommends a supplementation of 25 μg/day, while the 
American Academy of Pediatrics (AAP) (16) finds no evidence to supply the preterm 
infant with more than 10 μg/kg/day. Koo et al (58) measured plasma 25(OH)vitamin 
D concentrations in preterm infants receiving 5, 10 or 20 μg/day. They showed that 
plasma 25(OH)vitamin D remained normal for 6 months while infants received less 
than 10 μg /day. Further, Porcelli et al (59) substantiates the adequacy of vitamin D 
intakes in the range of 5 to10 μg /day for preterm infants.  
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Hypercalcemia due to vitamin D intoxication always accompanies 25(OH)vitamin D 
concentrations above 220 nM (60). A study from Japan (61) showed no 
hypercalcemia in VLBW infants on high intakes of supplemented vitamin D from 
formula (median intake 25 μg/day, 9-68 μg/day) with a plasma 25(OH)vitamin D 
concentration of 175 nM. The risk for hypercalcemia because of raised plasma 
25(OH)vitamin D concentrations is probably a reason for the study Backstrøm et al 
preformed on preterm infants (62). They showed that a dose of vitamin D of 5 μg/kg 
up to a maximum of 10 μg/day maintained normal vitamin D status and as good a 
bone mineral accretion as the recommended higher dose in Europe of 25 μg/day. 
1.5.3 Vitamin E 
The term vitamin E refers to eight naturally occurring compounds with characteristic 
biological activities.  Although the biological activities of the different vitamin E 
compounds vary, they all show antioxidant capability with the ability to protect 
cellular membranes from oxidative destruction initiated at the molecular level by 
lipid peroxidation (63). The most important group, the tocopherols, is characterized 
by a ring system and a long, saturated side chain. There are four members of this 
group: the α-, β-, γ- and δ-tocopherols, which differ only in the number and position 
of methyl groups in the ring. The second group, the tocotrienols, differs from the 
tocopherols by having an unsaturated side chain. The most active form of vitamin E, 
α-tocopherol, is also the most widely distributed in nature (64).  α-Tocopherol may be 
synthesized and is then called all-rac-α-tocopherol as the natural form is called RRR-
α-tocopherol. The supplement of vitamin E to the preterm infant comes as all-rac-α-
tocopherol bound to acetate (65).  
Although the biologic roles of vitamin E are numerous, they are poorly understood. 
To efficiently act as a radical scavenger α-tocopherol must be located in membrane 
sites well exposed to reactive oxygen species (66). While its hydrophobic character 
favours its integration into the bi-layer cell membrane, the conjugated isoprene side-
chain gives it an antioxidant property (67). It is also suggested that during vitamin E 
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deficiency states, the degeneration of the central nervous system that precedes the fall 
of plasma vitamin E concentration, may be linked to impaired neuronal protection 
against lipid peroxidation (67).  
The primary signs of vitamin E deficiency are reproductive failure, muscular 
dystrophy and neurological abnormalities. Among preterm infants vitamin E 
deficiency-induced haemolytic anaemia has been reported. This syndrome has been 
associated with the use of formulas that contain high levels of PUFAs with 
inadequate vitamin E while providing supplemental iron, which functions as an 
oxidant.  
The requirement for vitamin E increases when the intake of polyunsaturated fatty 
acids (PUFA) increases. Tsang et al (21) recommend an intake of at least 0.68 mg 
vitamin E/g linoleic acid in preterm infants. Absorption of α-tocopherol is variable, 
ranging from 20 to 80 % in various studies. Normal bile secretion and normal 
pancreatic function are essential for tocopherol absorption. Because of preterm 
infants’ low body stores of tocopherol, their reduced intestinal absorption and the 
relatively greater growth rates associated with prematurity, it is difficult for these 
infants to achieve and maintain normal vitamin E status. Since the preterm infants are 
born with low stores of tocopherol in addition to decreased blood concentrations, 
early provision is necessary to correct the depleted state and prevent adverse 
consequences attributable to insufficient antioxidants. In studies of enteral nutrition, it 
has been shown that a daily dose of 10-25 mg of α-tocopherol-acetate given to 0.6-
1.5 kg neonates may be required to produce and maintain normal vitamin E status 
(68). Oral supplementation of 17 mg of vitamin E per day may be required by 
preterm infants up to 3 months of age (21). Compared to other fat-soluble vitamins, 
vitamin E is relatively non-toxic when taken orally. The recommend intake of 
vitamin E for preterm infants vary from 5 to 17 mg/day (16;21). Treating VLBW 
infants with high dose vitamin E therapy has been proposed for preventing or limiting 
retinopathy of prematurity (ROP), intracranial haemorrhage, haemolytic anaemia and 
chronic lung disease (CLD) (69;70). A Cochrane report (71) concludes that this 
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therapy reduced the risk of intracranial haemorrhage and severe retinopathy, but 
increased the risk of sepsis. The conclusion is that evidence does not support the 
routine use of vitamin E supplementation by intravenous route at high doses, or 
aiming at serum levels greater than 81 μM. Doses of vitamin E exceeding 3.5 
mg/kg/day by the parenteral route or 25 mg/kg/day by the enteral route are 
considered pharmacological and should thus be regarded as experimental (45).   
Plasma concentration of α-tocopherol is commonly used to evaluate vitamin E status 
and a concentration of at least 12 μM indicates adequate nutritional status according 
to Farrell et al (72). The reference range for the plasma concentrations from Vitas AS 
is 16 to 36 μM for both adults and children. 
1.5.4 Vitamin K 
Vitamin K exists in two forms: 1. Vitamin K1 or phylloquinone which is the plant 
form, and 2. Vitamin K2, a series of compounds with unsaturated side chains, 
synthesized by bacteria and referred to as menaquinones. Animal tissue contains both 
phylloquinone and menaquinones (73). 
Compounds with vitamin K activity are essential for the formation of prothrombin 
and for at least five other proteins involved in the regulation of blood clotting. 
Although vitamin K is also required for the biosynthesis of some other proteins found 
in the plasma, bone and kidney, defective coagulation of the blood is the only major 
sign of vitamin K deficiency (73). 
Vitamin K1 has been reported to be present in low to undetectable concentrations in 
cord blood. There is no correlation between maternal and cord blood levels, and only 
very small amounts of vitamin K cross the placenta from mother to fetus (74). 
Under normal conditions, vitamin K is moderately well absorbed from the jejunum 
and ileum. Similar to all fat-soluble vitamins, vitamin K is absorbed from the 
intestine into the lymphatic system, requiring the presence of both bile salts and 
pancreatic secretions. Most of the bacteria comprising the normal intestinal flora of 
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human milk fed infants do not produce menaquinones, including Bifidobacterium, 
Lactobacillus and Clostridium species. Bacteria that produce menaquinones include 
Bacteroides fragilis and Escherichia coli, which are more common in formula fed 
infants (74). 
The newborn infant has low plasma prothrombin levels. Because human milk 
contains low levels of vitamin K (2 μg/l) and the intestinal flora are limited, 
exclusively breastfed infants who do not receive vitamin K prophylaxis at birth are at 
risk of developing fatal intracranial haemorrhage secondary to vitamin K deficiency.  
Vitamin K is routinely administered in large quantities at the time of birth. This 
routine prevents vitamin K deficiency bleeding (VKDB). This condition is most 
commonly seen in exclusively breastfed infants. VKDB comprises early (0-24 h), 
classic (1-7 d) and late (2-12 wk) syndromes according to the time of presentation 
(75). An intramuscular injection of vitamin K is routinely provided after birth, but  in 
some places oral solutions are administered (76). Such prophylaxis is still uncommon 
in many parts of the world today and even its use in Europe varies widely from 
country to country as well as within countries (77). In preterm infants who weigh 
more than 1 kg at birth, the standard dose of 1 mg of phylloquinone is appropriate 
and among infants less than 1 kg, a dose of 0.3 mg/kg of phylloquinone is 
recommended (16). Exclusively breast-fed preterm infants probably receive 
inadequate dietary vitamin K and may require further supplementation to protect 
against late-onset VKDB (78). 
Formulas for preterm infants provide sufficient vitamin K to meet daily needs 
thereafter. Lactating mothers easily achieve the recommended dietary allowance for 
vitamin K and the breast milk concentration is readily increased by increasing 
maternal vitamin K intake (77).  The use of human milk fortifiers that contain 
supplemental vitamins will provide the additional vitamin K needed to meet the 
recommended intake. For infants fed human milk, vitamin supplements of A, D and 
E are readily available as oral solutions. None of these contain vitamin K. If preterm 
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infants are discharged on standard term infant formulas, they may not receive the 
recommended amounts of this vitamin. 
Recommended intake of vitamin K for preterm infants varies from 2-3 μg/kg/day (48) 
to 7-9 μg/kg/day (16;21), but an intake as high as 100 μg/kg/day (79) has also been 
suggested. In addition, the recommendation involves prophylaxis at birth ranging 
from 0.1 mg to 1 mg intramuscularly or intravenously (80).  
The assessment of vitamin K status is dependent on the concentrations of different 
vitamin K dependent clotting factors. In the neonate these are 25-75% of normal 
adult concentrations and there is little difference at the time of birth between 30- and 
40-weeks-gestational age infants (81).  Injections of vitamin K do not significantly 
alter the measurements of these clotting factors. Thus, the difference in coagulation 
between adults and newborns cannot totally be ascribed to vitamin K deficiency (82) 
and the coagulation differences may be limited by the availability of precursor 
proteins rather than the availability of vitamin K. The reference range for plasma 
concentration of phylloquinone from Vitas AS is 0.1 to 2.2 ng/ml.  
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2. Aims 
The aim of the present study was to compare a modified vitamin A regimen to the 
reference protocol normally used in NICUs in Norway. In the modified protocol, the 
dose of vitamin A was increased by 8% compared to the supplementation of vitamin 
A to the infants on the reference regimen. The supplementation was given according 
to the infants’ actual weight and supplied continuously dispersed in the milk. The 
intervention aimed at increasing the plasma retinol concentration at discharge from 
hospital with the new supplementation regimen compared to the reference regimen.  
 
HYPOTHESIS 
Our main hypothesis was:  
1. VLBW infants in the modified protocol will have higher plasma retinol 
concentration at discharge from hospital, compared to infants in the reference group. 
The modified protocol introduced changes in the intake of the other fat-soluble 
vitamins D, E and K because of a different relative composition of vitamins in the 
modified supplement. We therefore hypothized:  
2. VLBW infants in the modified protocol will have lower plasma concentrations of 
25(OH)vitamin D compared to infants in the reference group. 
3.  VLBW infants in the modified protocol will have higher plasma concentrations of 
phylloquinone compared to infants in the reference group.  
4. VLBW infants in the modified protocol will have plasma concentrations of α-
tocopherol similar to the infants in the reference group. 
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3. Methods 
3.1 Study subjects 
All VLBW infants born between December 2003 and December 2005 at Akershus 
University Hospital were eligible for enrolment in an open intervention trial. 
Exclusion criteria were major congenital abnormalities, cerebral haemorrhage (grade 
3 or 4) as determined by ultrasound examination, death and parental disapproval. 
During the inclusion period, 68 VLBW infants were born and 8 were excluded due 
to: refusal from the parents (n = 3), not meeting eligibility criteria including death and 
diseases (n = 4), or moving to another hospital (n = 1). The included VLBW infants 
(n=60) were assigned either to the reference or the modified vitamin A regimen.  
Twenty-six infants in the reference group were included from December 2003 to 
September 2004, whereas 34 infants were enrolled in the modified group from 
October 2004 through November 2005. The two groups were comparable with regard 
to season variations, which may affect vitamin D status. 
Written, informed consent was obtained from the parents and the Regional Ethics 
Committee approved the study. The current study is part of an ongoing larger 
multicenter study on supplementation of essential fatty acids and cognitive function. 
 
3.2 Vitamin A supplementations 
Infants (n = 26) assigned to the standard treatment received enteral and parenteral 
nutrition, consistent with the routine regimen of our Neonatal Intensive Care Unit 
(NICU). This reference oral supplement included human milk fortified with proteins 
and minerals (Presemp; Semper AB, Stockholm, Sweden) and multivitamins 
(Multibionta; Trophen Merck, Darmstadt, Germany), providing 750 µg retinol 
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equivalents per day regardless of infant weight. The supplement was given as a bolus 
once daily.  
In the modified group (n = 34), the supplementation included a human milk fortifier 
with vitamins (Enfamil Human Milk Fortifier - Enfamil HMF; Mead Johnson 
Nutritionals, Evansville, Indiana, USA). The fortifier was dosed according to the 
infants’ milk requirement, based on actual daily weight; thus, the dose of vitamin A 
increased as the infant gained weight (Table 1). The median duration of the 
intervention was 8 weeks. 
Table 1. Daily intake of supplemented vitamin A by the reference and modified 
protocols. 
Infant body weight 
(examples) 
Reference protocol 
Presemp + Multibionta 
Modified protocol 
Enfamil HMF 
1,000 g  
750 µg 
 
513 µg 
1,500 g 770 µg 
2,000 g 1,026 µg 
The vitamin A intake values are based on a daily intake of 180 ml human milk/kg.            
HMF = human milk fortifier. 
 
3.3 Dietary intake 
Dietary intake of all VLBW infants during the neonatal period was calculated based 
on parenteral nutrition, human milk, formulas and oral supplements. The nutrient 
intake was calculated by a computer program (KBS; Department of Nutrition, 
University of Oslo, Norway) based on the Norwegian Food Composition Table (83). 
Data on commercially available products for preterm infants were obtained from the 
manufacturers and added to the database. Data on nutrient content in preterm human 
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milk (72 kcal, 3.5 g fat and 1.5 g protein per 100 ml) and donor milk were obtained 
from a report of Saarela et al (84). Data on vitamin A concentration in human milk 
from the food composition table were confirmed by high performance liquid 
chromatography (HPLC) analyses of 31 random milk samples from mothers in this 
study. Calculations were based on a mean concentration of vitamin A of 54 μg per 
100 ml human milk. When the infants achieved a daily enteral milk intake of 
approximately 150 ml/kg, the milk used for feeding the infants in the reference group 
was fortified with Presemp. These infants also received oral vitamin supplement 
(Multibionta) containing 750 µg of vitamin A (retinyl palmitate), 12.5 µg of vitamin 
D and 2 mg of vitamin E (α-tocopherol). They also received one additional daily 
dose of 15 mg vitamin E (Vitamin E-NAF, 50 mg/ml; Ås Produksjonslab AS, 
Norway) from birth till 32 weeks of gestational age. Infants in the modified group 
also received fortified human milk when the daily enteral intake reached 
approximately 150 ml/kg. The milk was fortified with proteins, vitamins and minerals 
from a multinutrient fortifier (Enfamil HMF). They also received one additional daily 
dose of 10 mg vitamin E from birth to 32 weeks of gestational age to match the 
vitamin E supplementation in the reference group. Ten of the infants in the reference 
group and 12 infants in the modified group received parenteral vitamins (Vitalipid 
Infant; Fresenius Kabi, Bad Homburg, Germany), up to 4 ml/kg for the first few days 
of life (median 1 day, interquartile range 0-7 days). The infants received additional 
0.5 mg vitamin K1 (Kanavit Tropfen®; Medphano, Berlin, Germany) every third day 
orally according to the protocol of the department.  
At discharge, 69% of the VLBW infants in the reference group and 64% of the 
VLBW infants in the modified group were breastfed, whereas the remaining infants 
were changed from donor human milk to term formula during the last days before 
discharge. When breastfeeding directly from the mother contributed with more than 
50% of the total milk volume, the infants started with a multivitamin supplement 
(Nycopluss Multi; Nycomed Pharma AS, Oslo, Norway). 
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3.4 Blood sampling and analyses of vitamins 
Venous blood samples (1 ml) from the VLBW infants were collected in EDTA 
containers at approximately one week of age and at discharge from the hospital. The 
blood samples were centrifuged, and plasma was stored at –80° C until further 
analyses. The plasma concentration of retinol, α-tocopherol, 25(OH)vitamin D and 
phylloquinone were measured by HPLC on a Hewlett Packard 1100 liquid 
chromatograph (Agilent Technologies; Palo Alta, CA, USA) with very high 
sensitivity. For detection of retinol, the method is linear at 0.1-10 µM and the lower 
limit of detection is 10 nM. The intra-assay coefficient of variation is 4.9-5.8 %, 
using known standards. For 25(OH)vitamin D, the method is linear at 5-400 nM and 
the lower limit of detection is 1-4 nM. CV is 5.2-5.8 %. For α- tocopherol, the 
method is linear at 1-200 µM and the lower limit of detection is 10 nM. CV is 4.6-4.8 
%. For phylloquinone, the method is linear at 0.05-4 ng/ml, and the lower limit of 
detection was 0.01 ng/ml CV is 7.8-10 %. 
 
3.5 Statistics 
Normally distributed data are presented as mean and standard deviation (SD). Non-
normally distributed data are presented as medians with interquartile range or 
minimum-maximum values. Categorical data are presented as percentages or actual 
numbers. Differences between groups were tested by the Mann-Whitney U test for 
continuous variables and Fisher’s exact test for categorical variables. The change in 
plasma retinol during the study was tested by ANOVA (general linear model, 
repeated measurements). Statistical significance was defined as a P value < 0.05. 
Power estimation was performed with plasma retinol as the primary end point. 
Initially we aimed at increasing the plasma retinol concentration from 0.30 to 0.70 
µM. To achieve this, the amount of supplementation could impose bloating and 
discomfort among the VLBW infants and even an increase to 0.50 µM is likely to be 
Comment [p1]: Putt in ref. 8 her 
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important.  Based on an earlier study (1), we estimated that we would need 25 infants 
in each group to detect a difference of 0.2 µM retinol, using a SD of 0.28 μM, 80% 
power and significance at 0.05.  
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4. Results 
4.1 Patients characteristics 
Three of the patients in the reference group and 4 in the modified group did not 
complete the study because of death or parent refusal, leaving 23 patients in the 
reference group and 30 patients in the modified group. Maternal and infant 
characteristics are presented in Table 2. The birth weight was 1,147 g vs. 1,155 g and 
the gestational age was 29.6 vs. 30.1 weeks in the reference group and modified 
group, respectively. No significant differences in patient characteristics were detected 
between the two groups at birth or enrolment.   
Table 2. Maternal and infant characteristics. 
 Reference protocol 
(n=26) 
Modified protocol 
(n=34) 
Birth weight (g) 1,147 1,155 
Birth length (cm) 38.0 37.8 
Gestational age (weeks) 29.6 30.1 
SGA at birth (%) 38.5 36.4 
Ratio male: female 1:1 1.4:1 
Maternal age (years) 30.0 30.5 
Maternal smoking (%) 22 22 
Data are presented as median (interquartile range) or percentages. There were no 
significant differences between groups. SGA = small for gestational age (weight < 10 
percentile for gestational age). 
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4.2 General feeding data 
Feeding was started in the two groups on similar days after birth (first or second), and 
supply of 150 ml/kg/day was reached at similar ages (Table 3). The numbers of 
infants fed human milk versus mixed fed infants (human milk and formula) were 
similar in the two groups (P>0.05). There was no significant difference between the 
two groups regarding the number of infants receiving parenteral nutrition (PN).  The 
two groups were also similar regarding the number of days the infants received PN 
during hospital stay. There was no significant difference for intake of energy (119 
vs.123 kcal/kg/day) or protein (3.2 vs. 3.4 g/kg/day). There was no significant 
difference in the median duration of the intervention in the two groups (62 vs. 57 
days) (Table 4). Moreover, there were no apparent differences in the incidence of 
feeding intolerance such as diarrhoea, abdominal distension or vomiting between the 
two groups (n = 2 in each group).  
Table 3. Feeding data.  
 Reference protocol
(n = 26) 
Modified protocol 
(n = 34) 
Enteral feed started: 
-first day  
-second day 
 
73 % 
27 % 
 
79 % 
21 % 
Duration of PN (days) 5  (2-7) 3.5 (2-7) 
Age when reached 150 ml/kg/day 
of enteral feeding (days) 
6 (5-7) 6 (5-7) 
Type of feeding: 
-human milk 
-mixed (human milk + formula) 
 
61 % 
39 % 
 
60 % 
40 % 
Data are presented as percent or median (interquartile range). There were no significant 
differences between groups. PN = parenteral nutrition. 
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4.3 Clinical events 
There was no significant difference between the two groups in median weight gain or 
weight at discharge from the hospital (Table 4). Furthermore, there was no 
significant difference in the incidence of the following events (Table 4): mechanical 
ventilation (35 vs. 41%), days of nasal continuous positive airway pressure (N-CPAP; 
6 vs. 8 days), median age at discharge (62 vs. 57 days) and days on antibiotics (1 vs. 
3 days). One infant in each group received postnatal steroid treatment of 
dexametasone 0.5 mg/day in three days. Two infants with extremely low birth weight 
(birth weight 705 g and 830 g) in the modified group, died. Their deaths were not 
related to feeding protocols: one infant had major congenital malformations, not 
detected at time of inclusion, and the other died of multiorgan failure. 
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Table 4. Clinical events. 
 Reference protocol 
(n=26) 
Modified protocol 
(n=34) 
Mechanical ventilation (%) 34.5 41.2 
Duration of mechanical ventilation 
(days) 
0 
(0-2) 
0 
(0-7) 
Duration of N-CPAP (days) 6 
(4-23) 
8 
(0-38) 
Age at discharge (days) 62 
(52-78) 
57 
(49-90) 
Antibiotic treatment (days) 1 
(0-3) 
3 
(0-6) 
Weight-gain (g/day) 26.6 
(23.0-29.7) 
25.6 
(22.7-27.7) 
Weight at discharge (g) 2,809 
(2,380-3,354) 
2,745 
(2,439-2,990) 
Mortality (number of infants) 0 2 
Data are presented as median (interquartile range) or percentages. There are no significant 
differences between groups. N-CPAP = Nasal Continuous Positive Airway Pressure. 
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4.4 Intake of the different fat-soluble vitamins 
The most important sources of fat-soluble vitamins were Vitalipid Infant if parenteral 
nutrition was given, and Multibionta or Enfamil HMF for enteral supplementation. 
The recommendations for the intake of the different fat-soluble vitamins are 
sometimes given per kg and sometimes given per day. Thus, to be able to compare 
the recommendations to the intake found in this study, the vitamin intakes per day are 
given in Table 5 while the vitamin intakes per kg are given in Tables 6, 7, 8 and 9. 
Table 5. Total intake of the different fat-soluble vitamins per day. 
Mean 
Median 
(interquartile range)  
 
Reference 
protocol 
 
Modified 
protocol 
 
P=valu
e 
 
Recommendations 
 
Vitamin A 
(µg) 
772 837  
P<0.01 
210-450 µg/kg/day (21) 
200-1000 µg/day (48) 
30-80 µg/kg (16) 
896 912 
670-938 652-1126 
 
Vitamin D 
(µg) 
10.6 9.5  
P<0.01 
3.75-10 µg/kg/day (21) 
25 µg/day (48) 
10 µg/kg/day (16) 
12.6 10.8 
11.5-12.6 7.7-12.6 
 
Vitamin E 
(mg) 
14.9 14.0  
P=0.59 
6-12 mg/kg/day (21) 
up to 17 mg/day 
5-15 mg/day (16) 
17.8 16.0 
17.3-18.0 8.7-19.5 
 
Vitamin K 
(µg) 
12.71 29.44  
P<0.01 
7-9 µg/kg/day (21) 
2-3 µg/kg/day (48) 
7-9 µg/kg/day (16) 
0.62 12.91 
0.47-0.77 6.09-15.72 
Data are presented as mean, median and interquartile range. 
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4.4.1 Intake of vitamin A 
Vitamin A intake related to gestational age is presented in Figure 1 for a more visual 
approach in addition to Table 5 and Table 6. During the total study period, infants in 
the modified group consumed slightly more vitamin A than infants in the reference 
group (585 vs. 546µg/kg/day; P =0.66).  Infants in the modified group received 
significantly more vitamin A than infants in the reference group during 3 out of the 4 
periods. The difference in vitamin A intake was greatest in the last period (gestational 
age > 37 weeks): 578 vs. 316 µg/kg/day (P = 0.02). This was due to increased intake 
of fortified human milk while the infants were gaining weight.  
 
 
 Figure 1. Intake of vitamin A at different gestational ages.                                
Data are presented as medians and interquartile range. There was a difference between the 
two groups during the observation period (ANOVA, P < 0.001).   
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Table 6. Intake of vitamin A. 
Vitamin A (µg/kg) 
Mean 
Median 
(interquartile range) 
 
Reference protocol 
n=26 
 
Modified protocol 
n=34 
 
P-value 
 
Total intake 
µg/kg/day 
537 524  
P=0.66 546 585 
321-691 414-645 
Period 1 
GA: < 28 weeks 
415 440  
P=0.06 154 213 
48-957 105-354 
Period 2 
GA: 29-32 weeks 
653 497  
P<0.01 685 590 
567-837 294-659 
Period 3 
GA: 33-36 weeks 
501 565  
P<0.01 506 600 
407-598 527-645 
Period 4 
GA: > 37 weeks 
361 469  
P<0.01 315 528 
232-413 235-611 
 
Recommendations 
 
210-450 µg/kg/day or 450-840 µg/kg/day with CLD (21) 
200-1000 µg/day (48)  
30-80 µg/kg/day (16) 
Data are presented as mean, median and interquartile range. GA= gestational age. 
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4.4.2 Intake of vitamin D 
During the total study period, infants in the reference group had a vitamin D intake 
higher than infants in the modified group (7.4 vs. 6.4 µg/kg/day; P<0.01). The 
difference in vitamin D intake per kg infant between the two groups was greatest in 
period 2 (GA=29-32 weeks), which is the time right after birth for many of the 
infants. We suspect this, as in vitamin A intake, to be due to the fact that vitamin 
supplementation was given according to the infants daily weight as opposed to the 
fixed, standard dose given to the reference group. The intake of the vitamin 
supplementations in the reference group given as a single fixed dose per day was 
declining per kg body weight throughout the study because of weight gain in the 
infant, while the vitamin supplementation intake in the modified group was kept 
constant per kg infant during the study period.  
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Table 7. Intake of vitamin D. 
Vitamin D (µg/kg) 
Mean 
Median 
(interquartile range) 
 
Reference protocol 
n=26 
 
Modified protocol 
n=34 
 
P-value 
 
Total intake 
µg/kg/day 
7.5 6.0  
P<0.01 7.4 6.4 
4.6-9.9 4.9-7.2 
Period 1 
GA: < 28 weeks 
6.0 6.0  
P=0.09 1.7 2.7 
0.03-14.8 0.1-4.5 
Period 2 
GA: 29-32 weeks 
9.3 5.7  
P<0.01 9.7 6.5 
7.6-12.0 3.3-7.3 
Period 3 
GA: 33-36 weeks  
6.8 6.4  
P=0.05 6.7 6.6 
5.3-8.2 5.9-7.1 
Period 4 
GA: > 37 weeks 
5.1 5.4  
P=0.06 4.3 5.9 
2.9-5.4 2.9-6.8 
Recommendations 
 
3.75-10 µg/kg/day (21) 
25 µg/day (48)  
10 µg/kg/day (16) 
Data are presented as mean, median and interquartile range. GA= gestational age. 
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4.4.3 Intake of vitamin E 
During the total study period the reference group and the modified group consumed 
the same amount of vitamin E, median values 10.4 vs. 10.3 mg/kg/day (P<0.01). The 
supplementation regimen was designed to provide equal doses of vitamin E in the 
modified and reference group. As Enfamil HMF contains vitamin E, the additional 
supplementation in the modified group was 10 mg as compared to the reference 
group who received 15 mg since Multibionta contains no vitamin E.  
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Table 8. Intake of vitamin E. 
Vitamin E (mg/kg) 
Mean 
Median 
(interquartile range) 
 
Reference protocol 
n=26 
 
Modified protocol 
n=34 
 
P-value 
 
Total intake 
mg/kg/day 
10.5 9.5  
 P<0.01 10.4 10.3 
7.1-13.8 5.1-13.0 
Period 1 
GA: < 28 weeks 
9.6 11.1  
P=0.08 4.3 5.3 
0.2-20.6 3.0-19.6 
Period 2 
GA: 29-32 weeks 
13.1 9.6  
P<0.01 13.6 11.3 
10.8-16.7 5.2-14.3 
Period 3 
GA: 33-36 weeks 
9.4 9.5  
P=0.01 9.5 10.7 
7.8-11.6 5.4-12.7 
Period 4 
GA: > 37 weeks 
6.4 6.9  
P=0.14 6.1 6.9 
2.8-7.5 4.3-10.4 
Recommendations 
 
6-12 mg/kg/day, up to max 17 mg/kg (21) 
No recommendations from ESPGHAN (48) 
5-15 mg/day (16) 
Data are presented as mean, median and interquartile range. GA= gestational age. 
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4.4.4 Intake of vitamin K 
In addition to the vitamin K intramuscular injection of 0.5 mg at birth, the ELBW 
infants received 0.5 mg vitamin K orally every 3rd day if they were given antibiotics 
or if there was any sign of liver affection. The VLBW infants in the same situation 
received 1 mg vitamin K orally every 3rd day. This routine in our and other neonatal 
intensive care units (NICU) explains the extremely high mean intake values in period 
1 (GA<28 weeks) in both groups (45.04 vs. 170.03 µg/kg/day; P<0.01). The intake of 
vitamin K in the reference group during the total study period was much lower than 
international recommendations, while the intake in the modified group was 
satisfactory due to supplementation of vitamin K from the milk fortifier, (0.38 vs. 
7.71 µg/kg; P<0.01).  
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Table 9. Intake of vitamin K. 
Vitamin K (µg/kg) 
Mean 
Median 
(interquartile range) 
 
Reference protocol 
n=26 
 
Modified protocol 
n=34 
 
P-value 
Total intake 
µg/kg/day 
12.61 29.36  
P<0.01 0.38 7.71 
0.34-0.42 4.95-8.62 
Period 1 
GA: < 28 weeks 
45.04 170.03  
P<0.01 0.45 48.39 
0.24-27.89 0.41-89.07 
Period 2 
GA: 29-32 weeks 
20.46 32.86  
P<0.01 0.39 7.76 
0.35-0.43 0.42-8.75 
Period 3 
GA: 33-36 weeks 
2.69 6.87  
P<0.01 0.37 7.77 
0.35-0.41 6.67-8.39 
Period 4 
GA: > 37 weeks 
1.75 5.84  
P<0.01 0.39 6.79 
0.29-0.49 0.32-7.96 
Recommendations 
 
7-9 µg/kg/day (21)  
2-3 µg/kg and in addition 0.5-1 mg IM injection (48) 
7-9 µg /kg and in addition 0.3-1 mg IM injection (16) 
Data are presented as mean, median and interquartile range. GA= gestational age. 
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4.5 Plasma concentrations of the fat-soluble vitamins at 
inclusion and discharge 
 
4.5.1 Plasma concentration of retinol 
At inclusion (6 days of age), both groups had low plasma retinol concentrations, and 
there was no significant difference between the two groups (0.54 vs. 0.43 µM). The 
plasma concentration of retinol in the reference group decreased during the study 
period, but remained constant in the modified group (Figure 2). At discharge from 
hospital the reference group had lower plasma retinol concentration as compared to 
the modified group (0.30 vs. 0.45 µM, P=0.005). The difference between the 
reference and modified group at discharge (61 days of age) was higher in infants that 
had received parenteral vitamins (0.30 vs. 0.59 µM, reference and modified group, 
respectively, P=0.006) compared to those only given enteral vitamin. At discharge, 
more infants in the reference group had plasma retinol concentrations less than 0.35 
µM as compared to the modified group (69 vs. 44%, P = 0.04) and many infants in 
both groups had plasma retinol concentrations below 0.70 µM: 88 vs. 73% in the 
reference and modified group, respectively. 
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Figure 2. Plasma retinol concentrations at inclusion (6 days of age) and 
discharge (61 days of age).  
The data are shown as box plots (minimum, 25th percentile, median, 75th percentile 
and maximum values), while outliers are shown as individual open circles. The 
plasma retinol concentration decreased on reference regimen during the study period, 
but remained constant in the modified group (ANOVA, P=0.012). 
 
4.5.2 Plasma concentration of 25(OH)vitamin D 
At inclusion (6 days of age), both groups had plasma concentrations in the normal 
range (Figure 3) and there was no significant difference between the two groups (81 
vs. 70 nM, reference and modified group, respectively). Both groups had a significant 
rise in plasma 25(OH)vitamin D concentrations from inclusion to discharge. In the 
reference group, plasma 25(OH)vitamin D at discharge was higher (171 nM) than the 
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reference level of 150 nM for term born infants at six months age. At discharge, 
infants in the reference group had higher plasma concentrations of 25(OH)vitamin D 
compared to corresponding values in the modified group (171 vs. 110 nM, P=0.005). 
Lower plasma 25(OH)vitamin D concentrations than internationally recommended   
(≤ 50 nM) were infrequent (one in each group).   
 
 
Figure 3. Plasma concentrations of 25(OH)vitamin D at inclusion and at 
discharge from hospital in the two groups.  
The data are shown as box plots (minimum, 25th percentile, median, 75th percentile 
and maximum values), while outliers are shown as individual open circles.  
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4.5.3 Plasma concentration of α-tocopherol 
At inclusion, the reference group had not significantly higher plasma α-tocopherol 
compared to the modified group (37 vs. 35 µM). At discharge from hospital there 
were no significant differences in plasma α-tocopherol concentration (31 vs. 39 µM) 
between the two groups. For the modified group, the median plasma concentration at 
discharge is slightly above the normal range (16-36 µM). 
 
Figure 4. Plasma concentration of α-tocopherol at inclusion and at discharge 
from hospital in the two groups.  
The data are shown as box plots (minimum, 25th percentile, median, 75th percentile 
and maximum values), while outliers are shown as individual open circles. 
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4.5.4 Plasma concentration of phylloquinone 
Plasma levels of phylloquinone differed between the groups of infants (Figure 5). At 
inclusion (6 days of age), plasma phylloquinone concentration in both groups was 
high, but the plasma concentration in the modified group was significantly higher 
then the concentration in the reference group (49.50 vs. 8.87 ng/ml, P=0.03). These 
are plasma concentrations much higher than the reference range (0.13-1.19 µM) 
given by the AAP (16), and may reflect that the immediately-after-birth dose is far 
too high. There was no significant difference in plasma phylloquinone (1.01 vs. 2.10 
ng/ml) between the two groups at discharge from hospital. 
 
Figure 5. Plasma concentrations of phylloquinone at inclusion and at discharge 
from hospital. 
The data are shown as box plots (minimum, 25th percentile, median, 75th percentile 
and maximum values), while outliers are shown as individual open circles.  
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5. Discussion 
5.1 Vitamin A and plasma retinol 
In this study of preterm infants weighing below 1500 g, two different vitamin A 
supplementation protocols were compared. In the modified protocol, infants received 
a higher daily dose of vitamin A, administered in a human milk fortifier, whereas 
infants in the reference group received vitamin A from a multivitamin supplement 
that was given as a bolus once a day. Our main finding was that infants in the 
modified group obtained higher plasma retinol levels at discharge from hospital as 
compared to the reference group. Importantly, more of the infants in the modified 
group reached plasma levels above 0.35 µM retinol, suggesting less vitamin A 
deficiency in this group. Many had plasma retinol concentrations below 0.70 µM, a 
level considered to be the lower limit for term infants and children (46). However, the 
optimal plasma retinol concentration for VLBW infants is not known and more 
research is needed to establish the optimal retinol concentration among this 
vulnerable group. 
The plasma retinol concentration may have varied during the hospital stay and 
extremely high or low levels, and the possible duration of these may not have been 
detected. The pharmacokinetics of vitamin A are likely to vary between infants, and it 
is not clear whether a nadir or steady state plasma retinol value is the most important 
factor in terms of vitamin A status. Furthermore, measuring plasma concentrations of 
retinol may not be sufficient to assess vitamin A status properly in preterm infants 
(44). Plasma retinol may reflect the availability of its carrier named retinol-binding 
protein (RBP), which is typically low in the preterm infant, whereas un-bound retinol 
is likely to be the most significant parameter for vitamin A status. Moreover, in 
preterm infants the level of RBP is correlated to the retinol concentration in plasma 
(67). The concentration of RBP increases in parallel with plasma retinol, without 
reaching levels that are considered normal in the pediatric population (67).  
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Vitamin A is an important nutrient in early infancy during rapid growth. The 
beneficial effects of vitamin A are due to its ability to promote growth and 
differentiation of epithelial tissues, including skin, immune system, intestine and 
lungs. Retinoic acid is a derivative of vitamin A, and acts as a ligand for nuclear 
receptors acting as transcription factors for genes involved in growth and 
differentiation of several types of cells (85). Deficiency of vitamin A is a 
predisposing factor for chronic lung disease, respiratory distress, retinopathy of 
prematurity and infections often seen in the VLBW infants (44). Furthermore, 
vitamin A is necessary for the health of the anterior eye and is an essential constituent 
of visual pigment. Microscopic conjunctive changes consistent with vitamin A 
deficiency have been noted in preterm babies, and low plasma vitamin A 
concentrations have been associated with the development of retinopathy of 
prematurity (44).  
Our present study confirms that preterm infants have low plasma concentrations of 
retinol at birth, and that in spite of supplementation, it is difficult to markedly 
increase retinol levels (47;86-88).This may be related to low intake, impaired 
absorption, higher requirements, inadequate transport and/or metabolism of vitamin 
A.  
Vitamin A may be supplied intramuscularly, parenterally or orally. Intramuscular 
vitamin A injections may reduce chronic lung disease and death in ELBW infants 
(49). Porcelli et al (89) found retinol concentrations > 0.70 µM four weeks after birth 
in ELBW infants receiving 318 µg/kg/day of vitamin A, mainly as a part of 
parenteral lipids, compared with infants receiving 234 µg/kg/day. Enteral 
supplementations contain vitamin A as retinyl esters, which have to be hydrolysed in 
the intestine prior to absorption. Wardle et al (90) reported that oral supplementation 
(1,500 µg/day) of vitamin A failed to give plasma retinol significantly higher than the 
control group at 28 days of life, neither did it alter the incidence of chronic lung 
disease. Kennedy et al (91) also concluded that large enteral doses of vitamin A led to 
lower plasma retinol concentrations compared to intramuscular injections. These data 
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suggest that absorption of retinyl ester may be a limiting factor in neonatal 
bioavailability of retinol.  
On the other hand, Delvin et al (67) reported that oral supplement containing 909 µg 
vitamin A gave adequate plasma retinol levels (on human milk to 0.84 µM and on 
formula to 1.01 µM) 30 days after birth. These infants had a higher birth weight 
(mean birth weight on human milk=1,746 g and on formula=1,795 g) than infants in 
our study. 
Landman et al (88) suggested that oral supplementation of 1,500 µg retinyl esters/day 
provided plasma concentrations similar to intramuscular injections (600 μg every 
second day), including only a small number of selected VLBW infants.  
Very high oral doses of retinyl esters efficiently reduce mortality in infants. In a 
randomised, double blind, placebo controlled trail with 11,619 newborn infants in 
South India, 7,200 µg of retinyl esters were given orally twice, on day 1 and day 2 
after delivery. This intervention promoted a 37 % decrease in mortality among infants 
with birth weight less than 2,000 g and beneficial differences in adverse events 
compared to placebo (92). We are not aware of studies that have tested such high 
doses in VLBW infants.  
Several studies show an increase in plasma retinol levels after intramuscular 
injections of vitamin A (50;87;93), and a high plasma retinol concentration protects 
ELBW infants against chronic lung disease and death (49). Intramuscular injection 
has not been implemented as routine treatment for preterm infants; the reasons 
reported from neonatal intensive care units are that the benefit of the treatment is 
regarded as small and not proven (51).  
Oral supplementation of 1,200 µg/kg/day of retinyl esters has been recommended for 
VLBW infants from start of full enteral feeding until discharge from the neonatal unit 
(43). In our present study, only 600 µg/kg/day was given using a commercially 
available human milk fortifier intended for preterm infants. Even though the plasma 
retinol levels at discharge were improved by the modified regimen, optimal retinol 
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levels might not have been reached. The amount of human milk fortifier cannot be 
increased beyond recommended doses, because it contains proteins and minerals. 
Future trials should therefore include increased amounts of retinyl esters in the human 
milk fortifiers.  
Another way of enhancing absorption may be to give unesterified retinol or a mixture 
of retinyl esters and retinoic acid (an active retinol metabolite). The advantage of 
giving free retinol is that the intestinal esterase would not be required before 
absorption. The mixture of retinyl esters and retinoic acid has been shown to increase 
the amount of retinyl esters in rat lung tissue compared to giving retinyl palmitate 
only (94). More studies are needed before this can be considered as a treatment 
option in humans.  
In summary, our modified protocol that was acceptable in means of dose and 
administration and well tolerated by the infants, improved vitamin A status at 
discharge and reduced the number of infants with low plasma retinol concentrations 
(below 0.35 μM) in VLBW infants, as compared to a reference protocol.  More 
studies are needed to establish the optimal plasma retinol concentration for preterm 
infants and how this can be achieved. 
 
5.2 Vitamin D and plasma 25(OH)vitamin D 
Vitamin D intake was different in the two groups. The group on the reference vitamin 
regime had a median vitamin D intake of 7.4 μg/kg/day. This is a significantly higher 
intake than in the modified group, which had a median vitamin D intake of 6.4 
μg/kg/day (Table 7). Since the recommendations for vitamin D intake is given as 
μg/day and not μg/kg/day, the relevant median vitamin D intake in the two groups 
were 12.6 μg/day vs. 10.8 μg/day (reference vs. modified group, respectively) (Table 
5).  In both groups this was lower than the recommendations in Europe (25 μg/day, 
according to ESPGHAN) (48), but matching the recommendations in America (10 
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μg/day, according to AAP) (16).  Nevertheless, we observed a significant rise in the 
plasma 25(OH)vitamin D concentration during the hospital stay in both groups.  
In the reference group, plasma 25(OH)vitamin D concentration was higher than the 
reference range, whereas the modified group had plasma 25(OH)vitamin D 
concentration in the upper part of the normal range. This may indicate that the 
recommendations for vitamin D supplementation need not be as high as 25 μg/day for 
human milk fed VLBW infants. Adequate plasma levels may probably be reached 
with a smaller daily dose, even lower than 10 μg/day (corresponding to 400 IE) since 
results given in this thesis show that even 12.6 μg/day seems to be too high. 
Plasma concentrations of 25(OH)vitamin D in preterm infants are 20-30% lower than 
the plasma levels of their mothers (57). Both in term-born and preterm newborns 
25(OH)vitamin D concentrations in cord blood are lower than those in maternal 
blood, and are correlated with concentrations in the mother (56). The vitamin D 
requirements of preterm infants are influenced by the body stores at birth, which in 
turn are related to the length of gestation and maternal stores. Preterm infants born 
after 28 weeks of gestation, appear to have the ability to absorb and hydroxylate 
vitamin D to produce 25(OH)vitamin D and the active metabolite 1,25(OH)2vitamin 
D from the first day of life (95-97). Vitamin D supplementation immediately after 
birth improves vitamin D nutritional status as evidenced by rising plasma 
25(OH)vitamin D concentrations. Concentrations of 1,25(OH)2vitamin D in preterm 
infants up to 3 months of age are more than 2-3 times higher than those seen in older 
children. During this period, there is no significant correlation between vitamin D 
metabolite concentrations and calcium and phosphorus intake. At 30 d of age, there is 
also no influence of diet or metabolite indexes (53). 
Adequate supplementation of vitamin D is, together with calcium, phosphorus and 
magnesium, essential for the formation of structural matrix of bone as well as 
function of soft tissues (98). Rickets is an example of extreme vitamin D deficiency. 
A state of deficiency occurs months before rickets is obvious on physical 
examination. 
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Vitamin D deficiency has been implicated in the etiology of the osteopenia of 
prematurity (99), but it is apparent that the main cause for this condition is a 
deficiency of calcium and phosphorus (100). Since absorption of calcium and 
phosphorus in preterm infants appears to be independent of vitamin D, it is unlikely 
that higher intakes of vitamin D would be beneficial (101). 
Early neonatal hypocalcemia affects 75% of preterm infants during the first days of 
life, principally those born with very low birth weights (<1500 g) (102). Long time 
effects of vitamin D supplementation in infancy have been shown to be associated 
with bone mineral content and increased bone mineral density in pre-pubertal girls 
(103). 
The effects of excessive vitamin D intake include hypercalcemia and hypercalciuria, 
leading to deposition of calcium in soft tissues and irreversible renal and 
cardiovascular damage. Serum 25(OH)vitamin D concentration higher than 220 nM 
is associated with hypercalcemia in adults (60). 
The recommended daily dose of vitamin D for preterm infants remains controversial 
and ranges between 5 (58) and 25 μg/day. The recommendations from AAP are to 
supply preterm infants with 10 μg/day (16). This is in contrast to the 
recommendations from ESPGHAN where preterm infants on human milk should be 
supplied with a vitamin D intake of 25 μg/day (48). 
Koo et al (58) measured plasma 25(OH)vitamin D concentrations in preterm infants 
receiving 5, 10 or 20 μg/day. They showed that plasma 25(OH)vitamin D remained 
normal for 6 months while infants received less than 10 μg/day. This is the key study 
to support the standard practice in North America and Australia, which is 
supplementation of a single daily dose of vitamin D of 10 μg/day. Backstrøm et al 
(62) reported that a daily vitamin D intake of 5 μg/day up to a maximum of 10 μg/day 
is sufficient for premature infants to maintain adequate vitamin D status. A recent 
study (59) substantiates the adequacy of vitamin D intakes in the range of 5-10 
μg/day. 
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The rationale for the higher intake of vitamin D for preterm infants recommended by 
ESPGHAN (48) with 25 μg/day, is the risk of sub-clinical vitamin D deficiency in 
women in Europe (and thus their newborn infants) owing to the lack of fortification 
of commercial cow milk with vitamin D. Maternal vitamin D deficiency will reduce 
the transplacental transfer to the fetus of 25(OH)vitamin D, resulting in lower stores 
in the infants at birth (57). However, in a clinical trial comparing 50 vs. 10 μg/day 
given to preterm infants fed human milk or standard term formula, no difference in 
metabolic bone disease as assessed radiologically was observed (104). Vitamin D 
status measured as the plasma concentration of 25(OH)vitamin D was within the 
normal range for both infant groups and at the upper limit of the normal range for 
those infants who received 50 μg/d.  In our study, plasma 25(OH)vitamin D 
concentration in the reference group supplemented with 12.5 μg/day indicates that 
supplementation in this range is too high and results in plasma concentration above 
the reference range. 
 
5.3 Vitamin E and plasma α-tocopherol 
In this study, both groups had similar intakes of vitamin E (10.4 vs. 10.3 mg/kg/day, 
reference and modified group, respectively). Since some of the recommendations for 
vitamin E intake are given irrespective of the infants’ weight (mg/day instead of 
mg/kg/day), the actual median vitamin E intake in the two groups were 17.8 mg/day 
vs. 16.0 mg/day. Supplementation of this amount is definitely higher than both the 
recommended intake of Tsang et al (21) of 4 to 8 mg/day and of Fewtrell & Lucas 
(10) of 5 mg/day. The dose of vitamin E given in this study gives plasma α-
tocopherol concentration at discharge from hospital within or just above the reference 
ranges (16-36 μM). The recommended daily dose of vitamin E varies between 6 and 
12 mg/kg/day and in both groups the daily supplementation doses were within the 
upper level of this reference intake range. 
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The biology of vitamin E, α-tocopherol being the most abundant and active form, is 
complex. Vitamin E is an antioxidant with the ability to protect cellular and 
subcellular membranes from oxidative destruction initiated at the molecular level by 
lipid peroxidation (63). In order to effectively act as a radical scavenger, α-tocopherol 
must be located at membrane sites well exposed to reactive oxygen species (66). 
Vitamin E may be considered as the primary defence against potentially harmful 
oxidants and signs of deficiency are reproductive failure, muscular dystrophy and 
neurological abnormalities.  
Total body content of α-tocopherol in the human fetus increases from about 1 mg at 5 
months gestation to approximately 20 mg at term (105). Because the preterm infant is 
born with low stores of α-tocopherol in addition to a decreased blood concentration, 
early provision of vitamin E is necessary to correct the depleted state and prevent 
adverse consequences attributable to insufficient antioxidants (16). 
Vitamin E requirements in preterm infants are not clearly defined possibly because 
the assessment of vitamin status is difficult to obtain. A concentration of at least 11.6 
μM (0.5 mg/dl) is thought to indicate adequate nutritional status in adults (72). Most 
would agree that vitamin E concentration in tissue is the most appropriate parameter 
to measure in order to assess vitamin E status, although in preterm infants, only blood 
concentrations are usually available.  In adults, tocopherol to total lipid ratio is 
considered to be a more appropriate test. Because of the marked influence of plasma 
lipids on circulating α-tocopherol concentrations, tocopherol data have been 
expressed as a function of the actual lipid concentration in many studies (72;106). 
These investigations have demonstrated that children do have significantly lower 
levels of plasma vitamin E than adults and a tocopherol-to-total lipid ratio of 0.6-0.8 
mg/g may indicate adequate nutritional status. This ratio might be important to 
measure in the VLBW infant, in whom changes in lipid levels occur, ranging from 
very low levels at birth to high during intravenous feedings of fatty acids. The 
requirement for vitamin E increases when PUFA intake increases. In extreme 
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situations, the need for α-tocopherol is suggested to vary from as little as 5 mg to 
more than 20 mg/day (66).  
Absorption of α-tocopherol is relatively inefficient, ranging from 20 to 80 % in 
various studies. Normal bile secretion and normal pancreatic function are essential. 
Premature infants present problems somewhat different from those of term-born 
infants of normal birth weight. Vitamin E deficiency is common among preterm 
infants receiving intensive care (21;107). Because of their low body stores of 
tocopherol, their reduced intestinal absorption and the relatively greater growth rates 
associated with prematurity, it is more difficult to achieve and maintain normal 
vitamin E status for these infants. Thus, oral supplementation of 17 mg/day of 
vitamin E may be required by premature infants up to 3 months of age (2) and 
compared to other fat-soluble vitamins, vitamin E is relatively non-toxic when taken 
orally. 
The Committee on Fetus and Newborn of the American Academy of Pediatrics (108) 
has endorsed 23 to 46 μM (1 to 2 mg/dl) as the normal range of serum tocopherol 
levels. Johnsen et al (109) has proposed classifying of serum tocopherol levels as 
physiologic in the range 23 to 81μM as appropriate for prophylaxis and treatment of 
early retinopathy of prematurity, and the pharmacologic range from 93 to 116 μM as 
appropriate for treatment of severe retinopathy of prematurity. A Cochrane review 
(71) has shown that vitamin E supplementation resulting in serum levels above 81 
μM, significantly reduces the risk for severe retinopathy among VLBW infants, but 
increases the risk of sepsis and of necrotizing enterocolitis (NEC) among infants 
treated for more than one week. Some institutions give pharmacological doses to 
infants that have developed the first stages of retinopathy of prematurity with 
successful results, including no more frequent episodes of sepsis or NEC (109).  
Vitamin E deficiency-induced haemolytic anaemia has been reported among preterm 
infants (48). This syndrome has been associated with the use of formulas that contain 
high levels of PUFAs with inadequate vitamin E while providing supplemental iron, 
which functions as an oxidant.  
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In studies of enteral nutrition, it has been shown that administration of 10-25 mg/day 
of water-miscible α-tocopherol-acetate given to neonates weighing 0.6-1.5 kg, may 
be required to produce and maintain normal vitamin E status (68;110). Some preterm 
infants receiving this amount of supplemented vitamin E, may not maintain a plasma 
α-tocopherol concentration above 12 μM, especially if they receive iron-fortified 
formula (111). 
 
5.4 Vitamin K and plasma phylloquinone 
Plasma phylloquinone concentrations in both groups were very high at inclusion 
compared to earlier studies in healthy newborns (74) and in preterm infants 
(1;112;113).  Similar to all fat-soluble vitamins, absorption is enhanced by dietary fat 
and is absorbed from the intestine into the lymphatic system, depending on the 
normal flow of both bile salts and pancreatic secretions. The low vitamin K plasma 
concentration in neonates is determined by a small transplacental passage from the 
mother to the infant (114) and compared to adults they have virtually no hepatic 
stores of menaquinones (vitamin K2). This vitamin is synthesized by bacteria of the 
gut. The lactobacillus intestinal microflora that is typical in breastfed infants does not 
synthesize menaquinones, and thus their vitamin K status is low. A new window, 
addressing physiology and safety, seems to have been opened by oral solutions, 
including mixed micellar or low-dose preparations of vitamin K (76). 
We demonstrated that during the hospital stay, the plasma phylloquinone 
concentration was significantly reduced in both groups, but the levels were still 
within the normal range (48). At discharge from hospital, infants in the modified 
group had higher phylloquinone concentration compared to the standard group, 
probably reflecting the higher intake in this group throughout the study (7.71 vs. 0.38 
μg/kg/day), i.e. plasma concentration seems to be correlated to the amount of vitamin 
supplemented.  
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The requirements and need at birth for such high doses of vitamin K as those given 
routinely in Norway, are not well documented. An intramuscular injection of vitamin 
K is routinely provided at birth to prevent bleeding in the newborn. Bleeding, 
however, is almost exclusively seen in breastfed infants. This may be explained by 
low plasma prothrombin levels in the newborn infant. Adding to this is that human 
milk contains low levels of vitamin K (2 μg/l) and the intestinal flora has not been 
established. Therefore, exclusively breastfed infants who do not receive vitamin K 
prophylaxis at birth may be at high risk of developing fatal intracranial haemorrhage. 
Vitamin K activity is essential for synthesis of prothrombin as well as at least five 
other proteins involved in the regulation of blood clotting. Vitamin K is also required 
for the biosynthesis of other proteins in plasma, bone and kidney. 
Several authors have suggested deleterious side effects from high vitamin K levels, 
such as childhood leukaemia and hepatoblastoma (115). Such findings have not, 
however, been confirmed by randomised studies. At present, it is not known whether 
high plasma vitamin K concentration in the neonatal period increases disease risks. 
However, this uncertainty should enhance attention of vitamin K supplementation in 
VLBW infants.  
In preterm infants who weigh more than 1 kg at birth, the standard dose of 1 mg of 
phylloquinone is used. Among infants less than 1 kg, a dose of 0.3 mg/kg of 
phylloquinone is recommended (16). 0.4 mg/kg of vitamin K intravenously to 
neonates, in whom oral or intramuscular administration is not feasible, seems to be 
rational (116). 
Prophylaxis is still uncommon in many parts of the world today. Even its use in 
Europe varies widely from country to country as well as within countries (77). 
Formulas for preterm infants provide sufficient vitamin K to meet daily needs 
thereafter. Human milk has low vitamin K content. Lactating mothers easily achieve 
the recommended dietary allowance for vitamin K and the breast milk concentration 
is readily increased by increasing maternal vitamin K intake (77). Human milk 
fortifiers that contain supplemental vitamins provide additional vitamin K needed to 
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meet the recommended intake of 7 to 9 μg/kg/day (48). For infants fed human milk, 
vitamin supplements of A, D and E are readily available as oral solutions, however, 
none of these contains vitamin K. Premature infants may therefore be discharged 
using formulas with insufficient vitamin substitution. Therefore, exclusively breast-
fed preterm infants probably receive inadequate dietary vitamin K and may require 
further supplementation to protect against late-onset VKDB (78). 
The recommended intake of vitamin K for preterm infants is not evidence-based, 
ranging from 2-3 μg/kg/day (48) to 100 μg/kg/day (79), with current prophylaxis at 
birth ranging from 0.1 mg to 1 mg IM or intravenously. 
Kumar et al (112) demonstrated that parenteral administration of large amounts of 
vitamin K in preterm infants at 2 weeks of age, resulted in high plasma vitamin K 
levels that were similar to those in term formula-fed infants. Therefore, also referring 
to the paper by Henriksen et al (1), we may argue that the parenteral vitamin K dose 
routinely given to preterm infants in Norway should be reduced. Lately, high doses of 
a water-soluble vitamin K (menadione) preparation has been shown to be associated 
with red cell haemolysis and hyperbilirubinemia, leading to kernicterus in the preterm 
infants (117). Therefore, current vitamin K supplementation of preterm infants, 
particularly at 2 weeks, provides excessive amounts of vitamin K and this has a 
potential for unforeseen side effects. 
Human milk generally contains less than 1 ug/dl. Supplementing mothers with 2.5 
mg vitamin K a day orally for two weeks increased the content of vitamin K in the 
milk to 6.42 μg/dl (118). Without this maternal supplementation, it would not be 
possible to supply these infants with even the minimal recommended Vitamin K 
intake for VLBW infants of 2 μg/kg/day. 
5.5 Methodological considerations 
The major strengths of this study are that it is conducted in a population of preterm 
infants fed fortified human milk and that we have detailed information on the intake 
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of vitamin A and plasma retinol measurements at start and end of the study. We 
further intended to obtain higher and acceptable plasma retinol concentrations by 
modifying the protocol for orally given vitamins and not by intravenous or 
intramuscular injections. There are, however, some limitations. Enrolled preterm 
infants were assigned in a cohort fashion to either the standard or modified nutrition 
regimen group. The cohort design was chosen for practical reasons, acceptable in the 
NICU. We recognize that the cohort design was not as desirable as a randomised 
prospective trial; however, the two groups were very similar regarding all aspects 
known to influence vitamin A status, and thus they were comparable. Corticosteroids 
are known to raise plasma retinol concentration. In this study only one infant in each 
group received corticosteroids for a short period of three days, so the plasma retinol 
concentration at discharge in this regard, probably reflects true vitamin A status. 
Another limitation of this study is that only two blood samples were collected, one at 
inclusion (median 6 days of age) and the second at discharge (median 61 days of 
age). 
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6. Conclusion 
The modified regimen improved the plasma concentration of vitamin A among 
VLBW infants at discharge compared to the reference protocol. The majority of 
infants in the reference group had plasma retinol concentrations below 0.35 μM 
compared to the modified group. This indicates lower hepatic stores in the reference 
group compared to the modified group and a more optimal vitamin A status in the 
latter. However, most infants in both groups had plasma retinol levels below 0.70 
μM. More studies are needed to establish the optimal plasma concentration for 
preterm infants and how this can be achieved.  
The status of vitamin D measured as plasma 25(OH)vitamin D concentration, 
improved in VLBW infants in the modified group compared to infants in the 
reference group. Infants in the modified group received smaller doses and obtained 
reference plasma levels as compared to infants on the reference protocol. Vitamin K 
status, measured as plasma phylloquinone concentration, did not significantly 
improve in infants in the modified protocol compared to those in the reference 
regimen. Vitamin E status, measured as plasma α-tocopherol concentration, was not 
significantly different in the two groups. 
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Appendix 2 
 
ERNÆRING, VEKST OG UTVIKLING BLANT PREMATURE BARN 
 
Vi holder på med en studie av ernæring, vekst og utvikling blant 200 premature (for tidlig 
fødte) barn med fødselsvekt under 1500 gram.  Alle barn som blir født eller innlagt ved 
Rikshospitalet, Sykehuset i Buskerud, Sykehuset i Vestfold eller Akershus 
Universitetssykehus i perioden 15.11.2003 til 15.11.2005 blir invitert til å delta i studien. 
Deltagelse er frivillig. Studien er vurdert og anbefalt av regional etisk komite. 
 
 
Bakgrunn: 
 
Små, premature barn har et annerledes og høyere næringsbehov enn barn som er født til 
termin. Deres eksakte behov er fortsatt ukjent.  Det er vanlig at barna får intravenøs 
ernæring (dvs. direkte i blodbanen) den første tiden. Mengden morsmelk trappes gradvis 
opp, i den takt som barnet tåler. Morsmelken gis via en sonde (et lite rør til magesekken) til 
barnet er i stand til å suge selv.   
 
Det er enighet om at morsmelk er den beste ernæring for premature barn, men morsmelk 
alene dekker likevel ikke næringsbehovet for de aller minste. Derfor er det vanlig å tilsette 
proteiner og mineraler til morsmelken.  Det er også vanlig å gi tilskudd av vitaminer, jern og 
folsyre  
 
Dersom det er behov for ekstra energi gis dette vanligvis i form av karbohydrater eller en 
blanding av karbohydrater/fett. Vi vet ikke nok om hvilken type fettsyrer som er best for 
premature barn på lang sikt. Formålet med denne studien er å sammenligne to ulike 
fettsyretilsetninger mens barnet ligger på sykehuset. Begge tilskuddene inneholder fettsyrer 
som er viktige for barnets vekst og utvikling, og som finnes naturlig i morsmelk.  
 
 
Hva innebærer dette for dere: 
 
• Moren vil bli spurt om sitt kosthold, bruk av kosttilskudd og røyking i svangerskapet 
• Etter fødselen vil det bli tatt en blodprøve fra navlestrengen 
• Barnet vil i tillegg til den gjeldende behandling få en av to typer vegetabilsk  
oljeblanding tilsatt i melken 
• Journalopplysninger om barnets inntak, vekst og sykdommer blir benyttet 
• Det vil bli tatt en prøve av morsmelken (ca 25 ml) 
• Det vil bli tatt blodprøve av barnet (ca 1 ml) to ganger under sykehusoppholdet 
• Dere vil få tilbud om en tverrfaglig undersøkelse av barnets vekst og utvikling, 
inkludert synsfunksjon ved 6 og 20 måneders alder 
 
 
Blodprøvene fra barnet og navlestrengsblodet vil bli analysert for fettsyremønster, 
fettløselige vitaminer og antioksidanter. Morsmelken vil bli analysert for fettsyremønster for 
å beregne barnas inntak av fettsyrer.  
 
Hva får dere igjen for å delta: 
  
• Alle barna vil få et ekstra energitilskudd, som kan være gunstig for vekst og utvikling 
hos barna. 
• Dere bidrar til at vi i fremtiden vil kunne gi bedre råd om ernæring til premature barn.  
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Behandling av data 
 
Dere kan trekke dere fra studien når som helst uten å måtte begrunne dette nærmere. 
Alle data vil bli behandlet i samsvar med Datatilsynets regler.  Blodprøvene vil ikke blir brukt 
til annet enn det som er beskrevet  over.  Alle persondata og eventuelt overflødig biologisk 
materiale vil bli ødelagt etter at studien er avsluttet. 
 
Din kontaktperson er:  
Christine Henriksen, Institutt for ernæringsforskning 
Telefon 22 85 15 26 
E-post: christine.henriksen@basalmed.uio.no 
 
Prosjektledere er: 
Professor Christian A. Drevon og professor Per Ole Iversen,  
Institutt for ernæringsforskning 
 
 
 
 
SAMTYKKE 
 
Undertegnede har fått skriftlig og muntlig informasjon om studien ”Ernæring, vekst og 
utvikling blant premature barn” og samtykker i deltagelse.   
 
 
 
Morens navn: ______________________________________________ 
 
Adresse:_________________________________________________ 
 
Telefon, hjem:_____________________________________________ 
 
Telefon, mobil:_____________________________________________ 
 
 
 
Oslo  /   -2005  ____________________________________________ 
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Appendix 3 
 
Fylles ut for alle deltagere i ernæringsstudien 
 
Nummer: ______ 
 
A. Sjekkliste 
 
 Utført
Underskrift samtykkeskjema 
 
 
Fyllt ut opplysninger om mor og barn  
(se baksiden) 
 
 
Levert spørreskjema om matvaner til mor 
NB! Noter nummeret 
 
 
Mottatt spørreskjema om matvaner 
 
 
Levert flaske til mormsmelksprøve 
 
 
Mottatt morsmelksprøve (4 uker) 
 
 
Gitt beskjed til behandlende sykepleier/lege 
og rekvirert blodprøve før oppstart av 
oljeblandingen (ved enteralt inntak 50-100ml 
melk/kg) 
 
 
Lagt bivirkningsskjema i journalen 
 
 
Gitt beskjed til melkekjøkken om nummer på 
flasken og oppstartsdato 
 
 
Ved evn overflytting til annet sykehus: 
• Gitt beskjed til lege/sykepleier 
• Sendt flasken med oljeblandingen 
 
Bedt behandlende lege om å rekvirert 
blodprøve før utskriving 
 
 
Kopiert kurve (inkl. bivirkningsskjemaet) 
og epikrise 
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B. Opplysninger om mor: 
 
Spørsmål Svar 
 
Hva er ditt fødselsår? 
 
 
Hva er din høyeste 
fullførte utdanning? 
 
1. Ungdomsskole (9 år eller mindre) 
2. Fagbrev e.l. (10-11 år) 
3. Videregående skole (12 år) 
4. Høyskole/universitet: (over 12 år) 
 
Hvor ofte røkte du 
sigaretter under 
svangerskapet? 
1. Aldri: 
2. 1-9 ganger: 
3. Flere ganger i måneden: 
4. 1 gang i uken 
5. 2-6 ganger i uken 
6. Daglig ___________ (antall) 
 
 
 
 
B. Opplysninger fra barnets journal 
 
Barnets navn:__________________________________________________ 
 
Barnets fødselsdato:___________________________________________ 
 
Kjønn:______________________________________________________ 
 
Navlestrengsblod ble tatt (ja/nei):_________________________________ 
 
Hvis ikke, angi årsak:___________________________________________ 
 
Fødselesvekt:________________________________________________ 
 
Gestasjonsalder:______________________________________________ 
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Appendix 4 
 
KODER for ernæringsprodukter brukt til premature barn: 
- 5173  Nan Ha 1, pulver 
- 5174  Nan Ha 1, drf 
- 5180  Nan 1, pulver 
- 5181  Nan 1, drf 
- 8078 Semper Energi 
- 9705 Biovit 
- 9743 Multibionta 
- 129001 Glukose 10 % 
- 129002 Glukose 5 % 
- 129003 Pedamix 
- 129004 Vaminolac 
- 129005 Intralipid 
- 129006 Vitalipid*Soluvit (Rikshopitalets løsning) 
- 129007 Vitalipid blanding (A-hus)  
- 129008 Morsmelk 
- 129009 Bankmelk 
- 129011 Prenan, pulver 
- 129012 Prenan HY, pulver 
- 129013 1/1 presemp + morsmelk 
- 129014 ½ presemp + morsmelk 
- 129015 1/1 presemp + bankmelk 
- 129016 ½ presemp + bankmelk 
- 129017 Presemp per pose 
- 129018 Super Soluble Duocal 
- 129020 Duocal MCT, pulver 
- 129022 Nycoplus Multi, flyt 
- 129023 Neo-fer, flyt 
- 129024 Folsyre, flyt 
- 129025 Vit E, flyt (kodes som mg, 15 mg = 0,3 ml) 
- 129026 Vit K, flyt (kodes som mg: 1 ml = 20 mg, 0,5 mg = 0,025 ml) 
- 129027 Nutramigen, pulver 
- 129028 Neocate, pulver 
- 129029 Profylac, pulver 
- 129030 Colett omega 3, flyt 
- 129031 Neocate, drf 
- 129032 Profylac, drf 
- 129033 Prenan HY, drf 
- 129034 Prenan, drf 
- 129035 1/1 Enfamil + morsmelk 
- 129036 ½ Enfamil + morsmelk 
- 129037 1/1 Enfamil + bankmelk 
- 129038 ½ Enfamil + bankmelk 
- 129039 Glukose 20% 
- 129040 Glukose 15 % 
- 129041 Enfamil HMF per pose 
- 129042 MCT-olje 
- 129043 Nutramigen, drf 
- 129044 Soluvit løst i intralipid (A-Hus blanding) 
- 129045 per 4 poser Enfamil HMF 
- 129046 Olivenolje (brukes på A-hus) 
- 129047 Soyaolje Mills (brukes telemark) 
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Appendix 5 
 
Eksempel fra tekstfilen der barnas næringsinntak ble registrert 
  
P 65001 1 xx.xx.xx 4 1460 1 (P = personlinje: randomiseringsnr 65, dag 001, fødselsdato xx.xx.xx, sykehusnr, fødselsvekt) 
K 1 (Daglinje: dag 1) 
M 129009 59 (Måltidslinje: barnet fikk 129009 som er bankemelk og mengden var 59 ml) 
P 65002 1 xx.xx.xx 4 1460 1 
K 2 
M 129009 135 9743 0.5 129024 0.5 129025 15 
P 65003 1 xx.xx.xx 4 1460 1 
K 3 
M 129009 152 9743 0.5 129024 0.5 129025 15 
P 65004 1 xx.xx.xx 4 1460 1 
K 4 
M 129009 157 9743 0.5 129024 0.5 129025 15 129049 0.79 
P 65005 1 xx.xx.xx 4 1460 1 
K 5 
M 129008 168 9743 0.5 129024 0.5 129025 15 129049 0.84 
P 65006 1 xx.xx.xx 4 1460 1 
K 6 
M 129008 199 9743 0.5 129024 0.5 129025 15 129049 0.99 
P 65007 1 xx.xx.xx 4 1460 1 
K 7 
M 129008 232 9743 0.5 129024 0.5 129025 15 129049 1.16 
P 65008 1 xx.xx.xx 4 1460 1 
K 8 
M 129008 232 9743 0.5 129024 0.5 129025 15 129049 1.16 
P 65009 1 xx.xx.xx 4 1460 1 
K 9 
M 129008 266 9743 0.5 129024 0.5 129025 15 129049 1.33 
P 65010 1 xx.xx.xx 4 1460 1 
K 10 
M 129008 280 9743 0.5 129024 0.5 129025 15 129049 1.4 
P 65011 1 xx.xx.xx 4 1460 1 
K 11 
M 129036 280 9743 0.5 129024 0.5 129025 15 129049 1.4 
P 65012 1 xx.xx.xx 4 1460 1 
K 12 
M 129035 305 9743 0.5 129024 0.5 129025 15 129049 1.53 
P 65013 1 xx.xx.xx 4 1460 1 
K 13 
M 129035 320 9743 0.5 129024 0.5 129025 15 129049 1.6 
P 65014 1 xx.xx.xx 4 1460 1 
K 14 
M 129035 332 129024 0.25 129025 10 129049 1.66 
P 65015 1 xx.xx.xx 4 1460 1 
K 15 
M 129035 336 129024 0.25 129025 10 129049 1.68 
P 65016 1 xx.xx.xx 4 1460 1 
K 16 
M 129035 335 129024 0.25 129025 10 129049 1.68 
P 65017 1 xx.xx.xx 4 1460 1 
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Appendix 6 
 
Ernæringsprosjekt: 
 
Resulterer i følgende næringstilskudd -  
 
Vitamintilskudd per os: 
Vitamin E (50 mg/ml) Start tilskudd samtidig med oppstart av Enfamil HMF,  
i redusert dose : 0.2 ml/dag. 
Barn som ikke får PN, kan starte med red. tilskudd av vitamin 
E som tidligere på dag 1. 
Folsyre (0.2 mg/ml) Start med tilskudd samtidig med oppstart av Enfamil HMF,   
i redusert dose : 0.25 ml/dag 
 
Parenteralt vitamintilskudd: 
Vitalipid Infant – blandes i Intralipid 
Soluvit – løses i 10 ml Intralipid, og 1 ml/kg gis 
 
Se eget skjema for beregning av vitamininntak 
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Appendix 7 
Ernæringsprosjekt: 
Opptrapping av parenteral og enteral ernæring 
 
 n = dag nr når morsmelk 120 ml/kg/døgn eller mer 
 Dag nr 
 iv ml/kg/døgn  
1 2 3 →  n n + 1 n+2 
       
Intralipid  2,5 5 10 10-15 5 0 
Vitalipid infant  1 2 4 4 2 0 
Soluvit 1 1 1 1 1  
Glukose/Pedamix iv Rest av døgnvolum  60 nedtrapping 
    
 Dag nr 
 per os (po) 
1 2 3 →  n n + 1 n+2 
    
Vitamin E (50 mg/ml)  0.2 0.2 
Folsyre (0.2 mg/ml)  0.25 0.25 
Jern (9 mg/ml) Oppstart fra ønsket 
tidspunkt 
0.75   2  
Morsmelk po 2-120 ** 0 0 
Morsmelk med HMF*   120  opptrapping 
*   antall poser/25 ml  1/2 1 
** forslagsvis    
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 Dag nr
 totalt 
1 2 3 →  n n + 1 n+2 
Resulterer i følgende 
næringstilskudd 
      
Vitami
n A 
iv ug/kg 69 138 276 276 138  
po ug/100 ml 
mm m/HMF 
    145 290 
Til beregning       
Vitami
n  E 
iv mg/kg 0.6 1.3 2.6 2.6 1.3  
po mg/100 ml 
mm m/HMF 
    1.6 3.1 
po mg tilskudd 
(50 mg/ml) 
    10 10 
Til beregning       
Folsyre iv ug/kg 40 40 40 40 40  
po ug/100 ml 
mm m/HMF 
    12.5 25 
po ug tilskudd 
(0.2 mg/ml) 
    50 50 
Til beregning       
PN fett g/kg 0.6 1.2 2.4 3.4 1.2  
SGA-barn: må vurderes nøye, ingen oppstart av tilsetninger før på fullt melkeinntak 
 
 
 
